Cathay Natural, LLC – FDA Warning Letter, Apr 3, 2020
On April 6, 2020, the FDA and FTC issued a Warning Letter to Cathay Herbs regarding their website, www.cathayherbs.com. The agencies reviewed the website on March 27, 2020, and April 3, 2020, respectively.
The FDA observed that Cathay Herbs offers herbal products for sale in the United States, claiming to mitigate, prevent, treat, diagnose, or cure COVID-19. These products are deemed unapproved new drugs, violating section 505(a) of the FD&C Act, 21 U.S.C. § 355(a), and misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).
The letter emphasizes the public health emergency declared for COVID-19. Cathay Herbs is required to immediately cease selling these unapproved and unauthorized products. The company must email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours, detailing corrective actions and providing supporting documentation. Failure to comply may result in legal
ID · 5372db31-d8cf-4993-9e95-b98b3c85096f
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.